Clinical Trials Logo

Clinical Trial Summary

The main aim of this study is to provide further information on the safety profile of HyQvia during pregnancy. This will be done by checking the characteristics of the mother and their babies. They will also be checked for any safety outcomes that will occur when exposed to HyQvia during pregnancy.


Clinical Trial Description

This is a non-interventional, retrospective, case series of commercially insured pregnant women exposed to HyQvia during their pregnancy identified according to the MarketScan Research Database. This study will assess maternal characteristics, patterns of HyQvia utilization and pregnancy outcomes in all pregnancies exposed to HyQvia during pregnancy. This study will enroll approximately at least 7 patients based on feasibility assessment. Participants will be enrolled in the following cohort: • HyQvia This study will have a retrospective data collection from 1 January 2014 to 31 December 2020. This study would be conducted in the US. The overall time for data collection in this study will be approximately 7 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05803200
Study type Observational
Source Takeda
Contact
Status Completed
Phase
Start date March 15, 2023
Completion date April 14, 2023

See also
  Status Clinical Trial Phase
Completed NCT01911767 - Biogen Multiple Sclerosis Pregnancy Exposure Registry
Active, not recruiting NCT04108728 - Neuropsychological Development and Executive Functioning of Children Born to HIV- Infected Mothers ( NEUROPSY-HEU ) N/A
Completed NCT04493892 - Hair Care Product Use Among Women Of Color N/A
Completed NCT02556775 - Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia
Not yet recruiting NCT04492449 - Evaluation of Systemic and Oral Conditions of Pregnant Women and Their Babies, With Exposure to COVID-19 Infection